Philadelphia University + Thomas Jefferson University

Fernandez, Sandra

< Back

Profile

svf004

Sandra Fernandez, PhD

Contact Dr. Fernandez

233 South 10th Street
Bluemle Life Science Building, Room 1002
Philadelphia, PA 19107

(205) 503-7316

Research & Clinical Interests

Dr. Sandra V. Fernandez focus is on the translational research and treatment of inflammatory breast cancer (IBC), the rare and aggressive form of breast cancer in which cancer cells block lymph vessels in the skin of the breast. She also has expertise in the development of novel diagnostic and prognostic markers in primary and metastatic breast cancer (MBC).

The research of Dr. Sandra V. Fernandez , in collaboration with Dr. Massimo Cristofanilli, aims to improve personalized medicine for breast cancer patients, focusing on molecular targeted agents, biomarkers and gene therapies, and bridging the gap between the bench and bedside in a more practical and smarter way.

Publications

Most Recent Peer-Reviewed Publications

  1. Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients
  2. Discovery of clinical candidate CEP-37440, a selective inhibitor of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK)
  3. The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells
  4. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations
  5. A preclinical model of inflammatory breast cancer to study the involvement of CXCR4 and ACKR3 in the metastatic process
  6. CTC enumeration and characterization: Moving toward personalized medicine
  7. TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients
  8. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: Preclinical activity in HER2 non-amplified inflammatory breast cancer models
  9. All trans-retinoic acid (ATRA) induces re-differentiation of early transformed breast epithelial cells
  10. Presence of anaplastic lymphoma kinase in inflammatory breast cancer
  11. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells
  12. Inflammatory breast cancer (IBC): Clues for targeted therapies
  13. Gene signatures of inflammatory breast cancer: Epithelial plasticity and a cancer stem cell phenotype
  14. Expression and DNA methylation changes in human breast epithelial cells after bisphenol A exposure
  15. Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas
  16. Estrogen, Alcohol Consumption, and Breast Cancer
  17. DNA methylation changes in a human cell model of breast cancer progression
  18. Estrogen and Xenoestrogens in breast cancer
  19. Human chorionic gonadotropin (hCG) prevents the transformed phenotypes induced by 17 β-estradiol in human breast epithelial cells
  20. Epithelial to mesenchymal transition in human breast epithelial cells transformed by 17β-estradiol